LY353381·HCl: An improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34)

Endocrinology

Volumn 139, Issue 11, 1998, Pages 4642-4651

  Sato, Masahiko ^a   Zeng, George Q ^a   Rowley, Ellen ^a   Turner, Charles H ^b  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARZOXIFENE; BENZOTHIOPHENE DERIVATIVE; CONJUGATED ESTROGEN; ESTROGEN; ETHINYLESTRADIOL; PARATHYROID HORMONE[1-34]; RALOXIFENE; UNCLASSIFIED DRUG; ANTIESTROGEN; PARATHYROID HORMONE; PIPERIDINE DERIVATIVE; THIOPHENE DERIVATIVE;

AGING; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HORMONAL THERAPY; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; BIOMECHANICS; BODY WEIGHT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFECT; HUMAN; ORGAN SIZE; OVARIECTOMY; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BIOMECHANICS; BODY WEIGHT; BONE DENSITY; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; ORGAN SIZE; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; PARATHYROID HORMONE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; THIOPHENES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85047679337     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.139.11.6307     Document Type: Article

References (58)

1. Weiss NS, Ure CI, Ballard JH, Williams AR, Daling JR 1980 Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 303:1195-1198
2. Lindsay R, Hart DM, Forrest C, Baird 1980 Prevention of spinal osteoporosis in oopherectomized women. Lancet 2:1151-1154
3. Quigley MET, Martin PL, Curnier AM, Brooks P 1987 Estrogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 156:1516-1523
4. Moore M, Bracker M, Sartoris D 1990 Long-term estrogen replacement therapy in postmenopausal women sustains vertebral bone mineral density. J Bone Miner Res 5:659-664
5. Lindsay R 1992 The effect of estrogens in prevention and treatment of osteoporosis. In: Munro H, Schlierf H (eds) Nutrition in the Elderly, Nestle Nutrition Workshop Series. Raven Press, New York, vol 29:161-167
6. Ziel HK, Finkle WD 1975 Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293:1167-1170
7. Smith DC, Prentice R, Thompson DJ, Herrmann WL 1975 Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293:1164-1167
8. Vesey MP 1984 Exogenous hormones in the aetiology of cancer in women. J R Soc Med 77:542-549
9. Steinberg KK, Thacker SB, Smith SC 1991 A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265:1985-1990
10. Dupont WD, Page DL 1991 Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151:67-72
11. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE 1997 Postmenopausal hormone therapy and mortality. N Engl J Med 336:1769-1822
12. Col NF, Eckman MH, Kras RH, Pauker SG, Goldberg RJ, Ross EM, Orr RK, Wong JB 1997 Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 277:1140-1147
13. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endomctrium in postmenopausal women. N Engl J Med 337:1641-1646
14. Bryant HU, Glasebrook AL, Yang NN, Sato M 1996 A pharmacological review of raloxifene. J Bone Miner Metab 14:1-9
15. Kaufman RF, Bryant HU 1996 Selective estrogen receptor modulators. DN&P 8:531-539
16. Sato M, Bryant HU 1996 Raloxifene efficacy in nonreproductive and reproductive tissues in rat models in vivo and in vitro. In: Kuramoto H, Gurpide E (eds) In Vitro Biology of Sex Steroid Hormone Action. Churchill Livingstone, Tokyo, pp 406-421
17. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU 1994 Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69
18. Sato M, Rippy MK, Bryant HU 1996 Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and non-reproductive tissues in ovariectomized rats. FASEB J 10:905-912
19. Sato M, Turner CH, Wang T, Adrian MD, Rowley E, Bryant HU, LY353381-HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. JPET, in press
20. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690-709
21. Tada K, Yamamura T, Okumura H, Kasai R, Takahashi H 1990 Restoration of axial and appendicular bone volumes by hPTH-(1-34) in parathyroidectomized and osteopenic rats. Bone 11:163-169
22. Mitlak BH, Williams DC, Bryant HU, Paul DC, Neer RM 1992 Intermittent administration of PTH-(1-34) increases serum 1,25 dihydroxyvitamin D concentrations and spinal bone density in senile (23 month) rats. J Bone Miner Res 7:479-484
23. Kimmel DB, Bozzato RP, Kronis KA, Kwong P, Recker RR 1993 The effect of recombinanat human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132:1577-1584
24. Li M, Wronski TJ 1995 Response of femoral neck to estrogen depletion and parathyroid hormone in aged rats. Bone 16:551-557
25. Li M, Mosekilde L, Sogaard CH, Thomsen JS, Wronski TJ 1995 Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone 16:629-635
26. Qi H, Li M, Wronski TJ 1995 A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats. J Bone Miner Res 10:948-955
27. Sato M, Zeng GQ, Turner CH 1997 Biosynthetic human PTH-(1-34) effects on bone quality in aged ovariectomized rats. Endocrinology 10:4330-4337
28. Sogaard CH, Mosekilde L, Thomsen JS, Richards A, McOsker JE 1997 A comparison of the effects of two anabolic agents (fluoride and PTH) on ash density and bone strength assessed in an osteopenic rat model. Bone 20:439-449
29. Reeve J, Hesp R, Williams D, Hulme P, Klenerman L, Zanelli J, Darby A, Tregear G, Parsons J 1976 The anabolic effect of low doses of human parathyroid hormone fragment on the skeleton in postmenopausal osteoporosis. Lancet 1:1035-1038
30. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OLM, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC 1980 Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicenre trial. Br Med J 280:1340-1344
31. Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM 1993 An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest 91:1138-48
32. Finkelstein J, Klebanski A, Schaefer E, Hornstein M, Schiff I, Neer R 1994 Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331:1618-1623
33. Sone T, Fukunaga M, Ono S, Nishiyama T 1995 A small dose of human parathyroid hormone (1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis. Miner Electrolyte Metab 21:232-235
34. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550-555
35. Kalu DN 1991 The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15:175-192
36. Wronski TJ, Yen CF 1991 The ovariectomized rat as an animal model for postmenopausal bone loss. Cell Mater 51:69-74
37. Frost HM, Jee WSS 1992 On the rat model of human osteopenias and osteoporoses. Bone Miner 18:227-236
38. Turner RT, Vandersteenhoven JJ, Bell NH 1987 The effects of ovariectomy and 17β estradiol on cortical bone histomorphometry in growing rats. J Bone Miner Res 2:115-122
39. Wronski TJ, Cintron M, Doherty AL, Dann LM 1988 Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats. Endocrinology 123:681-686
40. Durbridge TC, Morris HA, Parsons AM, Parkinson IH, Moore RJ, Porter S, Need AG, Nordin BEC, Vern-Roberts B 1990 Progressive cancellous bone loss in rats after adrenalectomy and oophorectomy. Calcif Tiss Int 47:383-387
41. Turner RT, Wakley GK, Hannon KS, Bell NH 1988 Tamoxifen inhibits osteoclast mediated resorption of trabecular bone in ovarian hormone deficient rats. Endocrinology 122:1146-1150
42. Kalu DN, Salerno E, Liu CC, Echon R, Ray M, Garza-Zapata M, Hollis BW 1991 A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat. Bone Miner 15:109-124
43. Moon LY, Wakley GK, Turner RT 1991 Dose-dependent effects of tamoxifen on long bones in growing rats: Influence of ovarian status. Endocrinology 129:1568-1574
44. Sato M, Kim J, Short LL, Slemenda CW, Bryant HU 1995 Longitudinal and cross-sectional analysis of Raloxifene effects on tibiae from ovariectomized aged rats. JPET 272:1252-1259
45. Sato M, Bryant H, Iversen P, Helterbrand J, Smietana F, Bemis K, Higgs R, Owan, Takano Y, Burr D 1996 Advantages of raloxifene over alendronate or estrogen on non-reproductive and reproductive tissues in the long-term dosing of ovariectomized rats. JPET 279:298-305
46. Ke HZ, Chen HK, Simmons HA, Qi H, Crawford DT, Pine CM, Chidsey-Frink KL, Ma YF, Jee WSS, Thompson DD 1997 Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model. Bone 20:31-39
47. Willson TM, Norris JD, Wagner BL, Asplin I, Baer P, Brown HR, Jones SA, Henke B, Sauls H, Wolfe S, Morris DC, McDonnell DP 1997 Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. Endocrinology 138:3901-3911
48. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL 1992 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856
49. Mosekilde L, Sogaard CH, McOsker JE, Wronski TJ 1994 PTH has a more pronounced effect on vertebral bone mass and biomechanical competence than antiresorptive agents (estrogen and bisphosphonate) assessed in sexually mature, ovariectomized rats. Bone 15:401-408
50. Shen V, Birchman R, Xu R, Otter M, Wu D, Lindsay R, Dempster D 1995 Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats. J Clin Invest 96:2331-2338
51. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610
52. Turner CH, Burr DB 1993 Basic biomechanical measurements of bone: a tutorial. Bone 14:595-608
53. Kimmel D 1996 Animal models for in vivo experimentation in osteoporosis research. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, San Diego, pp 671-690
54. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike WJ 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669
55. Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, Matsumoto K, Palkowitz AD, Sato M, Termine JD, Winter MA, Yang NN, Dodge JA 1997 Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 94:14105-14110
56. Yang NN, Venugopalan M, Hardikar S, Glasebrook A 1996 Identification of an estrogen response element activated by metabolites of 17B estradiol and raloxifene. Science 273:1222-1225
57. Evans GL, Bryant HU, Magee DE, Turner RT 1996 Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology 137:4139-4144
58. Evans GL, Bryant HU, Magee DE, Sato M, Turner RT 1994 The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134:2283-2288